IL-17 inhibitors rank highly for clearance of scalp, nail, and palmoplantar psoriasis
Biologics Show Different Success Rates for Scalp and Nail Psoriasis
This network meta-analysis of 5,946 patients evaluated IL-17/IL-23 axis biologics for difficult-to-treat psoriasis sites. The analysis found…
Different biologics show varying success rates for clearing psoriasis on the scalp, nails, and palms based on a large network analysis.
Delgocitinib and difamilast rank highest among nonsteroidal topical therapies for pediatric atopic dermatitis
New Topical Treatments Show Promise for Children with Eczema
This systematic review and network meta-analysis of 3,994 patients evaluated several novel nonsteroidal topical therapies for pediatric atop…
New nonsteroidal topical treatments like delgocitinib and difamilast show promise as steroid-sparing options for children with atopic dermat…
Multidisciplinary determination of resectability incorporates tumor biology and perioperative systemic therapy in stage III NSCLC
New Guidelines Redefine Surgery Options for Lung Cancer Patients
This clinical guideline addresses the management of stage III non-small cell lung cancer (NSCLC). It advocates for a multidisciplinary appro…
New guidelines suggest that surgery for certain lung cancers should be based on tumor biology and treatment response rather than just anatom…
Single-cell RNA sequencing identifies post-capillary venules and ADAM12+ fibroblasts as potential keloid targets
New research identifies specific cell types driving keloid scar growth
This meta-analysis of transcriptomic data uses single-cell RNA sequencing to identify cellular compositions in keloids across diverse ethnic…
Researchers identified specific blood vessel and skin cell types that may drive the growth of keloids across different ethnicities.
Microbiota-directed therapies for atopic dermatitis currently lack consistent human clinical evidence
Microbiome therapies for eczema still lack strong evidence
This narrative review examines microbiota-directed therapies including probiotics, postbiotics, and microbial metabolites for atopic dermati…
A new review finds that microbiome-based treatments for atopic dermatitis are promising but backed by limited human data.
FDA Approves Anzupgo (delgocitinib) for Moderate to Severe Chronic Hand Eczema
FDA approves new cream Anzupgo for chronic hand eczema in adults.
The FDA approved Anzupgo (delgocitinib) topical cream for moderate to severe chronic hand eczema in adults with inadequate response to topic…
The FDA approved Anzupgo (delgocitinib) cream for moderate to severe chronic hand eczema in adults who haven't improved with steroid creams.…
FDA Approves Cibinqo (abrocitinib) for Refractory Moderate-to-Severe Atopic Dermatitis
FDA approves new pill Cibinqo for hard-to-treat eczema in adults and teens.
The FDA approved Cibinqo (abrocitinib) for adults and pediatric patients 12 years and older with refractory moderate-to-severe atopic dermat…
The FDA approved Cibinqo (abrocitinib) for moderate-to-severe eczema in people 12 and older when other treatments fail. This new once-daily …
Mogamulizumab monotherapy achieves 41.2% overall response rate in patients with cutaneous T-cell lymphomas
Mogamulizumab Shows Meaningful Response in Cutaneous T-cell Lymphoma
This systematic review and meta-analysis of 453 patients evaluated mogamulizumab for Cutaneous T-cell Lymphomas, including Mycosis Fungoides…
New data shows mogamulizumab may be more effective for patients with Sézary Syndrome and blood involvement in certain skin cancers.
Long-term Safety Profile of Dupilumab in Adults with Moderate to Severe Atopic Dermatitis
Long-term dupilumab use shows low infection rates in skin conditions
A five-year open-label extension study confirms that dupilumab maintains a favorable safety profile regarding infection rates in adult patie…
A five-year study of adults with moderate to severe atopic dermatitis suggests that long-term dupilumab treatment is not linked to increased…
IO102-IO103 plus pembrolizumab improves progression-free survival in advanced melanoma patients
Trial shows combination therapy may extend time before melanoma progresses
This Phase III randomized controlled trial of 407 patients with untreated advanced melanoma evaluated IO102-IO103 (85 μg) combined with pemb…
A new clinical trial suggests that combining two specific drugs may help patients with advanced melanoma stay stable for longer periods.
Sentinel lymph node biopsy shows 9% positivity rate in patients with desmoplastic melanoma
Sentinel Lymph Node Biopsy Shows Specific Results for Desmoplastic Melanoma
This meta-analysis of 1671 patients evaluates sentinel lymph node biopsy (SLNB) for desmoplastic melanoma. The pooled SLN positivity rate is…
A review of data shows that sentinel lymph node biopsy has a 9% positivity rate in patients with desmoplastic melanoma.
Motivation-informed digital reminders do not improve task completion compared to standard wording in melanoma trial
Standard Digital Reminders Work Well for Melanoma Monitoring Tasks
This randomized study within a trial (SWAT) of 260 participants in a melanoma surveillance program found that motivation-informed digital re…
New research shows that standard digital reminders are just as effective as motivation-based ones for helping patients complete melanoma mon…
All Dermatology Articles
- IL-17 inhibitors rank highly for clearance of scalp, nail, and palmoplantar psoriasis
- Multidisciplinary determination of resectability incorporates tumor biology and perioperative systemic therapy in stage III NSCLC
- Delgocitinib and difamilast rank highest among nonsteroidal topical therapies for pediatric atopic dermatitis
- Single-cell RNA sequencing identifies post-capillary venules and ADAM12+ fibroblasts as potential keloid targets
- Microbiota-directed therapies for atopic dermatitis currently lack consistent human clinical evidence
- FDA Approves Anzupgo (delgocitinib) for Moderate to Severe Chronic Hand Eczema
- FDA Approves Cibinqo (abrocitinib) for Refractory Moderate-to-Severe Atopic Dermatitis
- Mogamulizumab monotherapy achieves 41.2% overall response rate in patients with cutaneous T-cell lymphomas
- EV-associated proteins and miRNAs provide high diagnostic accuracy for Lichen Planus and Oral Lichen Planus
- Motivation-informed digital reminders do not improve task completion compared to standard wording in melanoma trial
- Long-term Safety Profile of Dupilumab in Adults with Moderate to Severe Atopic Dermatitis
- Upadacitinib 30 mg tops JAK inhibitors for moderate-to-severe atopic dermatitis in network meta-analysis
- IO102-IO103 plus pembrolizumab improves progression-free survival in advanced melanoma patients
- Sentinel lymph node biopsy shows 9% positivity rate in patients with desmoplastic melanoma
- FDA Approves Skyrizi (risankizumab) for Ulcerative Colitis in Adults
- FDA Approves Skyrizi (risankizumab) for Ulcerative Colitis in Adults
- FDA Approves Absorica LD (isotretinoin) for Severe Recalcitrant Nodular Acne
- FDA Approves Absorica (isotretinoin) for Severe Recalcitrant Nodular Acne
- Nemolizumab Q4W improves IGA success maintenance by 11.8% over withdrawal in atopic dermatitis
- SSGJ-608 achieves 92.7% to 95.1% PASI75 response in moderate-to-severe plaque psoriasis
- Operating room nurses describe critical trauma management challenges and teamwork dynamics in a qualitative review
- FDA Approves Tremfya (guselkumab) for Ulcerative Colitis and Crohn's Disease
- Early preterm birth linked to lower atopic dermatitis risk in large meta-analysis
- ALK fusion Spitz neoplasms show distinct morphologic patterns and genomic correlates in meta-analysis
- Mohs micrographic surgery reduces local recurrence by 12% versus superficial radiation therapy in nonmelanoma skin cancer
- Quantitative PDA improves understanding and confidence versus qualitative PDA in dysplastic nevus screening
- High-certainty evidence suggests weight-loss interventions improve psoriasis severity and quality of life in adults
- Switching between adalimumab and biosimilar adalimumab-atto shows similar pharmacokinetics in plaque psoriasis
- Icotrokinra 200 mg daily achieves PASI 75 in 73% of patients at Week 16 versus 11% with placebo in moderate-to-severe plaque psoriasis
- Cadonilimab plus chemotherapy improves objective response rate to 0.62 in solid tumor patients
- Real-world meta-analysis of baricitinib for atopic dermatitis shows variable outcomes
- Secondary analysis of Phase 3 trials shows lebrikizumab improves absolute EASI response in moderate-to-severe atopic dermatitis
- Systematic review and meta-analysis of AI for melanoma risk assessment in pigmented skin lesions
- Narrative review explores gut microbiota links to atopic dermatitis pathogenesis and potential therapeutic strategies
- Review highlights emerging mechanisms for allergic contact dermatitis management
- FDA Approves Wezlana (ustekinumab-ttwe) for Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease, and Ulcerative Colitis
- FDA Approves Wezlana (ustekinumab-ttwe) for Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease, and Ulcerative Colitis
- Marburg MS case shows treatment challenges and fatal outcome
- FDA Approves Siliq (brodalumab) for Moderate to Severe Plaque Psoriasis
- Review of case report suggests multimodal therapy potential for unresectable intraductal papillary mucinous neoplasms of the bile duct
- Narrative review of treatment strategies for primary central nervous system lymphoma
- Narrative review offers theoretical basis for selecting biologic therapies in psoriasis patients with renal concerns
- Meta-analysis of sirolimus for cutaneous squamous cell carcinoma in kidney transplant recipients
- Psoriatic arthritis linked to interstitial lung disease prevalence
- Targeted therapies for psoriasis and psoriatic arthritis significantly alter lipid profiles across diverse patient populations
- Tralokinumab maintains efficacy in adults with moderate-to-severe atopic dermatitis up to 152 weeks
- Brodalumab Improves Palmoplantar Pustulosis in Japanese Adults in Phase 3 Trial
- 5-Fluorouracil and MAL-PDT vs Surgery for Bowen's Disease: 4-Year Outcomes
- Ixekizumab shows efficacy in children with enthesitis-related and juvenile psoriatic arthritis
- Meta-analysis finds early-stage cutaneous angiosarcoma linked to longer survival
- Rapid review and meta-analysis of psychological distress in adults undergoing Mohs micrographic surgery
- Systematic review shows regional differences in HS comorbidity prevalence across North America, Europe, and Asia
- Systematic review of advancements and challenges in NK cell immunotherapy for malignancies
- Preclinical study shows hydrogel microneedle patches sample microbes and immune cells in humans and mice
- Methodological study evaluates synthetic image framework for melanoma classification accuracy in preprint report
- Imsidolimab shows GPPPGA clearance in generalized pustular psoriasis flare at 4 weeks
- Systematic scoping review shows declining filarial infection prevalence in Latin America from 1946 to 2025
- Surgical excision in dromedary camels yields 83.70% recovery with 16.30% complications across cutaneous and subcutaneous masses
- Genetic burden in PI3K–AKT–mTOR pathway linked to microscopic polyangiitis susceptibility in Chinese cohort
- Stapokibart plus glucocorticoids achieves disease control in elderly bullous pemphigoid patients
- 675-nm Diode Laser as Adjuvant Therapy for Telogen Effluvium: A Retrospective Case Series
- Herring roe oil reduces inflammatory biomarkers in mild-to-moderate psoriasis
- Obinutuzumab-guided regimen achieves high remission in refractory membranous nephropathy patients
- Pilot RCT protocol assesses VR-PAT game versus dark screen for pain and anxiety in pediatric laser therapy
- FDA Approves Cosentyx (secukinumab) for moderate to severe plaque psoriasis in adults and pediatric patients 6 years and older
- FDA Approves Cosentyx (secukinumab) for Moderate to Severe Hidradenitis Suppurativa in Adults and Pediatric Patients
- MONO, ORM1, ORM2, and AGP levels show excellent diagnostic value for psoriasis identification in a retrospective case-control study
- Review suggests automated stool management system may reduce costs and nursing time in ICU fecal incontinence
- Review of cohort data finds AD linked to psoriasis risk and biologics associated with lower risk
- FDA Approves Stelara (ustekinumab) for moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis
- FDA Approves Stelara (ustekinumab) for moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis
- Review of chronic skin ulcers in Burkina Faso highlights Buruli ulcer prevalence in pediatric patients
- FDA Approves Abreva () for cold sores/fever blisters on the face or lips to shorten healing time and duration of symptoms
- Guselkumab Phase III trials validate 3VAS and 4VAS measures for psoriatic arthritis disease activity assessment
- Systematic review of public health interventions to curb respiratory infections at sporting mass gatherings
- Machine learning and deep learning applications in inguinal hernia care show promise for risk prediction and training
- Atopic constitution associated with severe Mycoplasma pneumoniae pneumonia in children
- Retrospective study links systemic BP control to better visual outcomes with conbercept for RVO-related macular edema
- Occupational noise exposure linked to cognitive decline in cross-sectional study of 170 workers
- Retrospective pediatric NTM study finds cervical lymphadenitis predominant, diagnostic delays common
- Phase 2 trial finds topical STS01 1% improves SALT scores in patchy alopecia areata
- Pivekimab sunirine shows activity in frontline and relapsed Blastic plasmacytoid dendritic cell neoplasm
- Network meta-analysis finds biologics superior to placebo for pediatric plaque psoriasis
- Outpatient IV sedation for dental care in special needs patients shows 3.3% minor complication rate
- Narrative review suggests endovascular treatment may be feasible and safe for posterior epistaxis
- Centralized hair loss measurement showed better agreement and 50% lower error margins than local rating in mild-to-moderate Alopecia Areata
- AI pipeline shows substantial agreement with dermatologists for grading atopic dermatitis erythema severity
- Meta-analysis compares HAQ-DI, SF36-PF, and SF36-PCS for physical function in psoriatic arthritis trials
- Early proactive TCS for infant AD linked to lower food allergy rates at age 3
- PD-L1 expression shows subtype-specific prognostic value in skin neoplasms, meta-analysis finds
- Bimekizumab maintains complete skin clearance in 73% of psoriasis patients at 4 years
- Retrospective analysis identifies molecular correlates of benefit with encorafenib-based therapy in BRAF-mutant melanoma
- Phase 2 trial: Topical STS01 shows dose-related hair regrowth in mild-moderate alopecia areata
- Meta-analysis finds oral JAK inhibitors increase HDL and LDL cholesterol levels in patients from RCTs
- Smartphone-based wound measurement shows excellent agreement with planimetry in single-center study
- Hair follicle-derived epithelial sheet transplantation shows repigmentation in stable vitiligo patients
- CDC recommends approaches to maintain tuberculin skin testing during expected Aplisol shortage
- Simulation study finds HEPA air cleaners and masking reduce exposure to simulated SARS-CoV-2 aerosols
- Report compares motor vehicle crash death rates across 29 high-income countries
- Case report: Initial positive measles IgM tests in two Samoan children were false positives
- Traffic-related death rates compared between US and 27 other high-income countries
- Report describes emergency department visits for traffic-related pedestrian injuries in the US
- Outbreak of Purpureocillium lilacinum fungal skin infections reported at Washington dermatology clinic
- Chinese APS-1 patients show recurrent AIRE gene deletion, male predominance, and low classic triad incidence
- Review analyzes PANoptosis mechanisms and potential treatments for ischemia-reperfusion injury
- Oral ME3183 shows higher PASI-75 response rates than placebo in moderate to severe plaque psoriasis trial
- Network meta-analysis ranks upadacitinib highest for efficacy in moderate-to-severe atopic dermatitis
- Placebo effect observed in double-blinded food challenges for dogs with atopic dermatitis
- Imiquimod costs substantially less than radiotherapy for lentigo maligna in Australian analysis
- Arthroscopy-assisted curettage and bone grafting for proximal femur giant cell tumor in a 25-year-old man
- Guselkumab Shows Improvement in Inverse Psoriasis in Single Case Report
- Nomogram predicts occupational contact dermatitis risk in Chinese nurses with excellent discrimination
- PFAS mixture exposure shows positive association with serum total IgE levels in Korean adults
- Topical PDE4 inhibitors show efficacy in pediatric atopic dermatitis meta-analysis
- Phase 2 study of lifileucel TIL therapy in 220 patients with metastatic melanoma
- Phase 3 trial of bimekizumab versus placebo in 435 adults with moderate to severe plaque psoriasis
- Phase 3 trial of low-dose IL-2 versus placebo for severe alopecia areata completed in 44 patients
- Phase II trial compares IMCgp100 vs investigator choice in advanced uveal melanoma
- Phase 2a study of bimekizumab in chronic plaque psoriasis reports pharmacokinetics and PASI change at Week 28
- Phase 3 Study Evaluates Barzolvolimab for Chronic Spontaneous Urticaria
- Sliding Cupping Therapy Matches NBUVB in Psoriasis Severity Reduction at 8 Weeks